Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07131163) titled 'Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection' on Aug. 3.
Study Type: Observational
Primary Sponsor: Sheba Medical Center
Condition:
Stage II-III Non-small Cell Lung Cancer
Recruitment Status: Recruiting
Date of First Enrollment: July 16, 2024
Target Sample Size: 60
Countries of Recruitment:
Israel
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07131163
Published by HT Digital Content Services with permission from Health Daily Digest....